Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
暂无分享,去创建一个
U. Dührsen | H. Serve | O. Ottmann | A. Schmidt | L. Wunderle | B. Wassmann | D. Hoelzer | M. Schmalzing | H. Pfeifer | M. Stelljes | T. Lange | A. Giagounidis | S. Wystub | P. Brück | J. Maier | A. Binckebanck | Ulrich Dührsen